3-[5-(4-cyclopropylphenyl)-1-methyl-1H-pyrazol-4-yl]-1-methyl-4-[3-(1-methyl-1H-pyrazol-3-yI)azetidin-1-yI]-1H-pyrazolo[3,4-d]pyrimdine | 1415637-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[5-(4-cyclopropylphenyl)-1-methyl-1H-pyrazol-4-yl]-1-methyl-4-[3-(1-methyl-1H-pyrazol-3-yI)azetidin-1-yI]-1H-pyrazolo[3,4-d]pyrimdine
• 英文别名: 3-[5-(4-Cyclopropylphenyl)-1-methylpyrazol-4-yl]-1-methyl-4-[3-(1-methylpyrazol-3-yl)azetidin-1-yl]pyrazolo[3,4-d]pyrimidine；3-[5-(4-cyclopropylphenyl)-1-methylpyrazol-4-yl]-1-methyl-4-[3-(1-methylpyrazol-3-yl)azetidin-1-yl]pyrazolo[3,4-d]pyrimidine
• CAS: 1415637-69-2
• 化学式: C₂₆H₂₇N₉
• 分子量: 465.561
• InChiKey: FQNAZGGPBVCNDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  82.5
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS
  申请人：Helal Christopher John

  公开号：US20140080806A1

  公开（公告）日：2014-03-20

  The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors.

  本发明提供了公式(I)的化合物及其药学上可接受的盐，以及制备这些化合物所使用的中间体、含有这些化合物的组合物和将这些化合物用作哺乳动物中治疗中枢神经系统疾病、认知障碍、精神分裂症、痴呆和其他疾病的方法。本发明还提供了公式(Id)的化合物及其药学上可接受的盐作为CYP3A4选择性抑制剂。
• US8829010B2
  申请人：——

  公开号：US8829010B2

  公开（公告）日：2014-09-09